Soligenix announces submission of new drug application to the fda for hybryte™ in the treatment of cutaneous t-cell lymphoma

Princeton, n.j. , dec. 15, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it submitted a new drug application (nda) to the united states (u.s.) food and drug administration (fda) for hybryte™ (synthetic hypericin) in the treatment of early stage cutaneous t-cell lymphoma (ctcl), a rare cancer and area of unmet medical need affecting over 25,000 patients in the u.s.  the company estimates the potential worldwide market for hybryte™ to be in excess of $250 million for the treatment of ctcl.
SNGX Ratings Summary
SNGX Quant Ranking